The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Background and purpose
Cardiovascular risk factors and comorbidities can affect the prognosis of multiple sclerosis (MS). The Framingham risk score is an algorithm that can estimate the 10‐year risk of developing macrovascular disease. Our objectives were to evaluate the possible association between the Framingham risk score at baseline and MS relapses, disability, and disease‐modifying therapy (DMT) choices over a 5‐year follow‐up.
Methods
This is a retrospective cohort study including 251 MS subjects. At baseline, we calculated the Framingham risk score considering the following variables: age, sex, diabetes, smoking, systolic blood pressure, and body mass index. MS outcomes including relapses, disability, and treatments were collected over 5 years. Cox proportional regression models were employed to estimate hazard ratios (HRs).
Results
A one‐point increase in the Framingham risk score was associated with 31% higher risk of relapse (HR = 1.31; 95% confidence interval [CI] = 1.03, 1.68), 19% higher risk of reaching of EDSS 6.0 (HR = 1.19; 95% CI = 1.05, 3.01), and 62% higher risk of DMT escalation (HR = 1.62; 95% CI = 1.22, 3.01).
Conclusions
Higher cardiovascular risk was associated with higher risk of relapses, disability, and DMT escalation in MS. Early identification, correction, and treatment of cardiovascular comorbidities should be carefully considered within MS management.
Cardiovascular risk factors and comorbidities can affect the prognosis of multiple sclerosis (MS). The Framingham risk score is an algorithm that can estimate the 10‐year risk of developing macrovascular disease. Our objectives were to evaluate the possible association between the Framingham risk score at baseline and MS relapses, disability, and disease‐modifying therapy (DMT) choices over a 5‐year follow‐up.
Methods
This is a retrospective cohort study including 251 MS subjects. At baseline, we calculated the Framingham risk score considering the following variables: age, sex, diabetes, smoking, systolic blood pressure, and body mass index. MS outcomes including relapses, disability, and treatments were collected over 5 years. Cox proportional regression models were employed to estimate hazard ratios (HRs).
Results
A one‐point increase in the Framingham risk score was associated with 31% higher risk of relapse (HR = 1.31; 95% confidence interval [CI] = 1.03, 1.68), 19% higher risk of reaching of EDSS 6.0 (HR = 1.19; 95% CI = 1.05, 3.01), and 62% higher risk of DMT escalation (HR = 1.62; 95% CI = 1.22, 3.01).
Conclusions
Higher cardiovascular risk was associated with higher risk of relapses, disability, and DMT escalation in MS. Early identification, correction, and treatment of cardiovascular comorbidities should be carefully considered within MS management.
Date Issued
2021-03
Date Acceptance
2020-10-18
Citation
European Journal of Neurology, 2021, 28 (3), pp.893-900
ISSN
1351-5101
Publisher
Wiley
Start Page
893
End Page
900
Journal / Book Title
European Journal of Neurology
Volume
28
Issue
3
Copyright Statement
© 2020 European Academy of Neurology. This is the accepted version of the following article: Petruzzo, M., Reia, A., Maniscalco, G.T., Luiso, F., Lanzillo, R., Russo, C.V., Carotenuto, A., Allegorico, L., Palladino, R., Brescia Morra, V. and Moccia, M. (2021), The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis. Eur J Neurol., which has been published in final form at https://doi.org/10.1111/ene.14608
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000591078500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
cardiovascular
disability
multiple sclerosis
relapse
DISABILITY PROGRESSION
CIGARETTE-SMOKING
BRAIN ATROPHY
FOLLOW-UP
DISEASE
MS
COMORBIDITIES
RELAPSE
PROFILE
LIFE
Publication Status
Published
Date Publish Online
2020-10-22